Brokers Offer Predictions for GeoVax Labs FY2029 Earnings

GeoVax Labs, Inc. (NASDAQ:GOVX) – Stock analysts at Roth Capital issued their FY2029 earnings estimates for shares of GeoVax Labs in a research report issued on Friday, March 28th. Roth Capital analyst J. Aschoff anticipates that the company will earn $12.20 per share for the year. The consensus estimate for GeoVax Labs’ current full-year earnings is ($4.49) per share.

GeoVax Labs (NASDAQ:GOVX) last announced its earnings results on Thursday, March 27th. The company reported ($0.30) EPS for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.49. The business had revenue of $3.00 million for the quarter, compared to analysts’ expectations of $2.38 million.

Separately, D. Boral Capital reissued a “buy” rating and set a $18.00 price target on shares of GeoVax Labs in a report on Friday, March 28th. Five investment analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company. According to MarketBeat, GeoVax Labs has an average rating of “Buy” and an average price target of $14.20.

GeoVax Labs Price Performance

NASDAQ:GOVX opened at $1.08 on Monday. The firm has a market capitalization of $10.19 million, a price-to-earnings ratio of -0.19 and a beta of 3.06. GeoVax Labs has a one year low of $1.03 and a one year high of $11.18. The business has a fifty day moving average price of $1.62 and a 200-day moving average price of $2.10.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Northern Trust Corp bought a new stake in GeoVax Labs during the fourth quarter valued at about $29,000. Geode Capital Management LLC grew its position in shares of GeoVax Labs by 59.0% during the fourth quarter. Geode Capital Management LLC now owns 90,139 shares of the company’s stock worth $223,000 after purchasing an additional 33,440 shares in the last quarter. Virtu Financial LLC bought a new stake in GeoVax Labs during the 3rd quarter valued at approximately $97,000. Finally, Citadel Advisors LLC purchased a new position in GeoVax Labs in the 4th quarter worth approximately $104,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

About GeoVax Labs

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.